A practical reference on Cardarine: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-12. Anything still debated is marked as such rather than presented as settled.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Come What(ever) May is the second studio album by American rock band Stone Sour, released on August 1, 2006, by Roadrunner Records. It was recorded and produced by Nick Raskulinecz and the band at Studio 606 in Los Angeles, California. Writing for the album began as early as 2003 when vocalist Corey Taylor and guitarist James Root were writing material for their other band, Slipknot. In January 2006, Stone Sour began recording their second album, during which time drummer Joel Ekman left the band because of family constraints. He was eventually replaced by ex-Soulfly drummer Roy Mayorga who played on all but two tracks on the album. Following the release of the album, Stone Sour promoted it for over a year, releasing five singles and touring in the United States, Canada, Japan and several countries in Europe. The album received generally positive reviews. It was praised for showing a progression in the band's songwriting ability and musical style. It was also certified Platinum in the United States and the single "30/30-150" was nominated for Best Metal Performance at the 49th Grammy Awards. On June 26, 2007, Stone Sour released a special edition version of the album; it included six previously unreleased tracks and a bonus DVD with three music videos and a complete live performance by the band in Moscow. It remains their best-selling album to date, mostly due to the success of the single "Through Glass". The album became their first to be certified Platinum by the RIAA which occurred on July 21, 2017.
=== Prohibited content === Facepunch Studios blacklists servers that are malicious, depict sexual violence, or contain content that is not safe for work but not marked as such. In April 2023, following a Twitter poll with close to 50,000 respondents, the company additionally banned the glorification of Nazism, including the display of swastikas and the Nazi salute.
(CH2CH2)O → •CH2CH2O• → CH2O + CH2: When carrying the thermal decomposition of ethylene oxide in the presence of transition metal compounds as catalysts, it is possible not only to reduce its temperature, but also to have ethyl as the main product, that is to reverse the ethylene oxide synthesis reaction.
Efraim Halevy (Hebrew: אפרים הלוי; born in London, 2 December 1934); Israeli intelligence expert and diplomat; was director of Mossad and 3rd head of Israeli National Security Council; author of Man in the Shadows, covering Middle Eastern history since the late 1980s; nephew of Sir Isaiah Berlin; has written for The Washington Post, Jerusalem Post, Times of Israel, Haaretz, Foreign Affairs, Ynet News, The Forward Simon Hattenstone (born 29 December 1962 in Salford, England) journalist and writer; features writer and interviewer for The Guardian. He has also written or ghost-written a number of biographical books. Paula Heimann; (2 February 1899 – 22 October 1982), author, academic, psychiatrist and psychoanalyst who established phenomenon of countertransference as important tool of psychoanalytic treatment, publishing influential studies, texts, academic papers and monographs; member of British Psychoanalytical Society; author of monograph A contribution to the problem of sublimation and paper On counter-transference, presented at the Psychoanalytical Congress in 1949 in Zurich, led to rift with Kleinian group of analysts; later turned to the Independents group and was Margarete Mitscherlich's analyst; Alexander Mitscherlich also underwent training analysis with her. Margot Heinemann (18 November 1913 – 10 June 1992) was a British Marxist writer, drama scholar, and leading member of the Communist Party of Great Britain (CPGB).
== Early life == Markin was born and raised in Lincoln, Nebraska. He received a Bachelor of Science degree in 1977 from Nebraska Wesleyan University, where he majored in chemistry with minors in mathematics and physics. He received a Ph.D. in chemistry from the University of Nebraska–Lincoln in 1980; he earned his medical degree from the University of Nebraska Medical Center (UNMC) in 1983; he completed his residency in pathology and laboratory medicine at UNMC in 1986. He has been on the UNMC faculty since 1986. His professional and academic research interests have focused on clinical laboratory automation including robotics, information systems, medical utilization management, business efficiency modeling, adult and pediatric pathology, liver/gastrointestinal pathology, telehealth, telemedicine, technology development and mobile health.
Sources: en.wikipedia.org
The particular series of amino acids that form a protein is known as that protein's primary structure. This sequence is determined by the genetic makeup of the individual. It specifies the order of side-chain groups along the linear polypeptide "backbone". Proteins have two types of well-classified, frequently occurring elements of local structure defined by a particular pattern of hydrogen bonds along the backbone: alpha helix and beta sheet. Their number and arrangement is called the secondary structure of the protein. Alpha helices are regular spirals stabilized by hydrogen bonds between the backbone CO group (carbonyl) of one amino acid residue and the backbone NH group (amide) of the i+4 residue. The spiral has about 3.6 amino acids per turn, and the amino acid side chains stick out from the cylinder of the helix. Beta pleated sheets are formed by backbone hydrogen bonds between individual beta strands each of which is in an "extended", or fully stretched-out, conformation. The strands may lie parallel or antiparallel to each other, and the side-chain direction alternates above and below the sheet. Hemoglobin contains only helices, natural silk is formed of beta pleated sheets, and many enzymes have a pattern of alternating helices and beta-strands. The secondary-structure elements are connected by "loop" or "coil" regions of non-repetitive conformation, which are sometimes quite mobile or disordered but usually adopt a well-defined, stable arrangement. The overall, compact, 3D structure of a protein is termed its tertiary structure or its "fold".
In March 1997, the company patented this combination. The drug was approved in June 1997, by the FDA as Imodium Multi-Symptom Relief in the form of a chewable tablet. A caplet formulation was approved in November 2000. In November 1993, loperamide was launched as an orally disintegrating tablet based on Zydis technology. In 2013, loperamide was added to the WHO Model List of Essential Medicines.
t1/2: Biological half-life tmax: Time to achieve maximum plasma concentration pKi: the measurement of ligand binding affinity Methylnaltrexone bromide has poor oral bioavailability, and for that reason, every other day it is administered subcutaneously. About half of the dose is excreted in the urine and somewhat less in feces with 85% eliminated unchanged. Alvimopan has considerable low bioavailability (6%) due to its high binding affinity and low dissociation rate. Essentially, alvimopan is mediated by biliary secretion with an average plasma clearance of 400 ml/min. Metabolism of alvimopan is via intestinal flora resulting in hydrolysis of alvimopan to the active amide metabolite (ADL 08-0011). However, the metabolite is considered clinically irrelevant due to its low binding affinity. When naloxegol is given with a fatty meal, absorption increases. Clearance is mostly via hepatic metabolism (P450-CYP3A) with unknown actions of the metabolites. Naloxegol has small fragments eliminated by renal excretion. Naldemedine metabolites mainly via CYP3A to nor-naldemedine, it also metabolites via UDP-glucuronosyltransferase 1A3 to naldemedine 3-G, but in a lesser extent. Those metabolites are both opioid receptor antagonists but are less potent than the parent compound.
Bariatric surgery is an effective method for obese and diabetic individuals with MASLD to induce weight loss and reduce or resolve MASH inflammation, including fibrosis, and improve longevity. For the AASLD, bariatric surgery can be considered only for MASH on a case-by-case basis by an experienced bariatric surgery program. Indeed, some individuals might develop new or worsened features of MASLD. About 92% of people with MASLD experienced an improvement in steatosis, and 70% a complete resolution after bariatric surgery. A preoperative diet such as a low-calorie diet or a very-low-calorie diet is usually recommended to reduce liver volume by 16–20%. Preoperative weight loss is the only factor associated with postoperative weight loss. Preoperative weight loss can reduce operative time and hospital stay, although there is insufficient evidence whether preoperative weight loss reduces long-term morbidity or complications. Weight loss and decreases in liver size may be independent of the amount of calorie restriction. The APWG on MASLD recommends bariatric surgery as a treatment option for those with class II obesity (BMI >32.5 kg/m2 for Asians, 35 kg/m2 for Caucasians). They consider its effects on improving liver-related complications as unproven yet, but it effectively increases longevity by improving cardiovascular factors. Surgery carries more risks for individuals with MASH cirrhosis, with a review estimating overall morbidity to be 21%.
Sources: en.wikipedia.org
The substrates of this enzyme are D-glyceric acid, oxidised nicotinamide adenine dinucleotide (NAD+), and carbon dioxide. Its products are 2-hydroxy-3-oxosuccinic acid, reduced NADH, and a proton. The enzyme can use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-glycerate:NAD(P)+ oxidoreductase (carboxylating). This enzyme participates in glyoxylate and dicarboxylate metabolism.
Placing flat hands on the floor with straight legs Left knee bending backward Right knee bending backward Left elbow bending backward Right elbow bending backward Left thumb touching the forearm Right thumb touching the forearm Left little finger bending backward past 90 degrees Right little finger bending backward past 90 degrees
Ionic flow in action potentials at Blackwell Publishing Action potential propagation in myelinated and unmyelinated axons at Blackwell Publishing Generation of AP in cardiac cells and generation of AP in neuron cells Resting membrane potential from Life: The Science of Biology, by WK Purves, D Sadava, GH Orians, and HC Heller, 8th edition, New York: WH Freeman, ISBN 978-0-7167-7671-0. Ionic motion and the Goldman voltage for arbitrary ionic concentrations at The University of Arizona A cartoon illustrating the action potential Action potential propagation Open-source software to simulate neuronal and cardiac action potentials at SourceForge.net Introduction to the Action Potential, Neuroscience Online (electronic neuroscience textbook by UT Houston Medical School) Khan Academy: Electrotonic and action potential Archived 2 July 2014 at the Wayback Machine
== Canada, United States of America, Europe == Abdul Rahman Ibrahima Sori (c. 1762 – 1829) – Son of Ibrahim Sori Mawdo of Futa-Jallon. Enslaved in Natchez, Mississippi but freed and repatriated to Liberia. Alhaji Mohammed Ayuba Suleiman Diallo (also known as Job ben Solomon) – Trader, then slave. Freed and repatriated to his homeland in Boundou, Senegal Bill Hamid Diaryatou Bah - French female activist. Moussa Diallo Elhadj - Senator, Belgian Senate. Philippe Diallo - President of French Football Federation Nafissatou Thiam - Three time heptathlon Olympic Gold Medalist, Hepthathlon World Record Holder. Satou Sabally - German-American Female Basketballer, Three time WNBA All star, WNBA Most Improved Player (2023), All-WNBA First Team (2023). Nyara Sabally - German Female Basketballer, WNBA champion 2024. Abou Diaby - former Arsenal and French National team Player. Romane Dicko - Two time single judo olympics bronze medalist, two time mixed olympics Gold medalist. Ousmane Dembélé - french national team player, Ballon D'or 2025 Elladj Baldé - Canadian figure skater. He won the 2015 Nebelhorn Trophy, an ISU Challenger Series event. He is the 2008 Canadian Junior champion. Boris Diaw - French basketball player Alexander Bah - Danish football player Djibril Sidibé (footballer, born 1992) - French World cup winner.
Validation and verification of medical devices ensure that they fulfil their intended purpose. Validation or verification is generally needed when a health facility acquires a new device to perform medical tests. The main difference between the two is that validation is focused on ensuring that the device meets the needs and requirements of its intended users and the intended use environment, whereas verification is focused on ensuring that the device meets its specified design requirements.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.